華潤醫藥(03320.HK)附屬獲批設置單採血漿站
華潤醫藥(03320.HK)公佈,旗下華潤博雅生物獲江西省衛生健康委員會頒發《關於同意泰和縣設置單採血漿站的批覆》(贛衛醫字(2023)65號)及《關於同意樂平市設置單採血漿站的批覆》(贛衛醫字(2023)66號),將在泰和縣和樂平市設置單採血漿站。
華潤博雅生物表示,將依據《單採血漿站基本標準》、《單採血漿站質量管理規範》等相關法律法規及標準要求建設相關單採血漿站,並將在建成後根據《單採血漿站管理辦法》等有關要求提交執業申請,經驗收合格後開展採漿工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.